Li Yuanzhe, Yang Debin, Zhao Huan, Dou Liping, Chen Qian, Cheng Yibing, Hu Bo, Tang Yu, Duan Yongtao, Guo Caili, Sakandar Abbas, Li Dong
Department of Pediatrics, The First Affiliated Hospital of Dalian Medical University, Dalian116011, China.
Henan Provincial Key Laboratory of Children's Genetics and Metabolic Diseases, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou, 450018, China.
J Transl Med. 2025 Jun 17;23(1):661. doi: 10.1186/s12967-025-06674-1.
Dysbiosis of intestinal microecology caused by sepsis plays a crucial role in the onset and progression of sepsis-induced acute lung injury (SALI). As a postbiotic type, inactivated probiotic bacteria can regulate the gut microbiome. Pasteurized bacteria are considered safer than live bacteria in immune dysregulation disorders. Weissella cibaria (W. cibaria) is considered a candidate probiotic with certain beneficial functions. However, whether inactivated W. cibaria can alleviate SALI and the underlying mechanisms remain unclear. This study aimed to investigate whether inactivated W. cibaria can regulate intestinal mucosal barrier function and gut microbiota, thereby improving SALI.
Following gavage of pasteurized W. cibaria in septic mice, lung tissue damage and inflammation levels were assessed. Circulating LPS levels and inflammatory cytokine concentrations in the blood were measured. Additionally, colonic tissue inflammation, intestinal mucosal barrier integrity, and alterations in the gut microbiota were evaluated.
Pasteurized W. cibaria increases survival rates in SALI mice and improves pathological damage and cell apoptosis in lung tissue. Pasteurized W. cibaria also reduces the lung inflammatory response in septic mice by lowering pro-inflammatory cytokine levels and increasing anti-inflammatory cytokine levels. Pasteurized W. cibaria appears to exert its effects by improving the intestinal mucosal barrier and reversing gut microbiota dysbiosis caused by sepsis. Specifically, pasteurized W. cibaria alleviates intestinal barrier damage and inflammation in SALI mice, enhancing the integrity of the intestinal mucosal barrier. Additionally, pasteurized W. cibaria increases the abundance of anti-inflammatory bacteria such as Muribaculaceae. Pasteurized W. cibaria also decreases the levels of LPS-producing bacteria, including Escherichia-Shigella and Helicobacter, leading to significant attenuation in metabolic endotoxemia, which in turn alleviates excessive lung inflammation in septic mice.
Pasteurized W. cibaria has the potential to act as a postbiotic agent, improving sepsis-induced gut microbiota dysbiosis and acute lung injury, and providing a novel strategy for treating SALI.
脓毒症引起的肠道微生态失调在脓毒症诱导的急性肺损伤(SALI)的发生和发展中起关键作用。作为一种后生元类型,灭活益生菌可调节肠道微生物群。在免疫失调疾病中,巴氏杀菌细菌被认为比活细菌更安全。魏斯氏菌(W. cibaria)被认为是具有某些有益功能的候选益生菌。然而,灭活的W. cibaria是否能减轻SALI及其潜在机制仍不清楚。本研究旨在探讨灭活的W. cibaria是否能调节肠道黏膜屏障功能和肠道微生物群,从而改善SALI。
对脓毒症小鼠灌胃巴氏杀菌的W. cibaria后,评估肺组织损伤和炎症水平。测量血液中循环脂多糖(LPS)水平和炎性细胞因子浓度。此外,评估结肠组织炎症、肠道黏膜屏障完整性以及肠道微生物群的变化。
巴氏杀菌的W. cibaria可提高SALI小鼠的存活率,并改善肺组织的病理损伤和细胞凋亡。巴氏杀菌的W. cibaria还通过降低促炎细胞因子水平和增加抗炎细胞因子水平来减轻脓毒症小鼠的肺部炎症反应。巴氏杀菌的W. cibaria似乎通过改善肠道黏膜屏障和逆转脓毒症引起的肠道微生物群失调来发挥其作用。具体而言,巴氏杀菌的W. cibaria可减轻SALI小鼠的肠道屏障损伤和炎症,增强肠道黏膜屏障的完整性。此外,巴氏杀菌的W. cibaria增加了诸如毛螺菌科等抗炎细菌的丰度。巴氏杀菌的W. cibaria还降低了包括大肠杆菌 - 志贺氏菌属和幽门螺杆菌在内的产LPS细菌的水平,导致代谢性内毒素血症显著减轻,进而减轻脓毒症小鼠的过度肺部炎症。
巴氏杀菌的W. cibaria有潜力作为一种后生元制剂,改善脓毒症诱导的肠道微生物群失调和急性肺损伤,并为治疗SALI提供一种新策略。